DeFalco et al., 2018 - Google Patents
Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigensDeFalco et al., 2018
View HTML- Document ID
- 12507458624916667696
- Author
- DeFalco J
- Harbell M
- Manning-Bog A
- Baia G
- Scholz A
- Millare B
- Sumi M
- Zhang D
- Chu F
- Dowd C
- Zuno-Mitchell P
- Kim D
- Leung Y
- Jiang S
- Tang X
- Williamson K
- Chen X
- Carroll S
- Santo G
- Haaser N
- Nguyen N
- Giladi E
- Minor D
- Tan Y
- Sokolove J
- Steinman L
- Serafini T
- Cavet G
- Greenberg N
- Glanville J
- Volkmuth W
- Emerling D
- Robinson W
- Publication year
- Publication venue
- Clinical Immunology
External Links
Snippet
There is significant debate regarding whether B cells and their antibodies contribute to effective anti-cancer immune responses. Here we show that patients with metastatic but non- progressing melanoma, lung adenocarcinoma, or renal cell carcinoma exhibited increased …
- 102000004965 antibodies 0 title abstract description 131
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DeFalco et al. | Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens | |
| Lahiri et al. | Lung cancer immunotherapy: progress, pitfalls, and promises | |
| Gang et al. | CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas | |
| Papachristofilou et al. | Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer | |
| Verma et al. | PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+ CD38hi cells and anti-PD-1 resistance | |
| Lopez-Albaitero et al. | Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody | |
| Ahmed et al. | Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma | |
| Geldres et al. | T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo | |
| CN112512575B (en) | Bispecific antibody compositions and methods of use thereof | |
| Dimitrov | Therapeutic antibodies, vaccines and antibodyomes | |
| US20180044415A1 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
| Seyfrid et al. | CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment | |
| Lettieri et al. | Progress and opportunities for immune therapeutics in osteosarcoma | |
| IL303785A (en) | Chimeric antigen and t cell receptors and methods of use | |
| CN107207580A (en) | Anti- CLDN Chimeric antigen receptors and application method | |
| AU2021250858A1 (en) | Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells | |
| Jung et al. | Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8+ T cells for cancer immunotherapy | |
| Perez-Santos et al. | LAG-3 antagonists by cancer treatment: a patent review | |
| Rosenzweig et al. | Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis | |
| CN109923127A (en) | The combination of anti-BAG3 antibody and immunologic test point inhibitor for therapeutic use | |
| Vandeven et al. | Rationale for immune-based therapies in Merkel polyomavirus-positive and-negative Merkel cell carcinomas | |
| Park et al. | Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape | |
| Cohen et al. | Predictors of T cell expansion and clinical responses following B-cell maturation antigen-specific chimeric antigen receptor T cell therapy (CART-BCMA) for relapsed/refractory multiple myeloma (MM) | |
| Van Den Eeckhout et al. | Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication | |
| Jensen-Jarolim et al. | Cancer vaccines inducing antibody production: more pros than cons |